ETOP RAISE

A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer. RAISE: Niraparib added to anti-PD-L1 antibody maintenance in SLFN11-positive, extensive-disease SCLC

Summary of the study

An international, multicentre, single-arm phase II trial in patients with extensive-disease small cell lung cancer and high SLFN11-expression who have not progressed during first-line standard chemo-immunotherapy and are planned for maintenance therapy with immune-checkpoint inhibition .

Further study information

Further Studies: Lung cancer

Recruitment completed

SAKK 16/18

Immunotherapy and radiotherapy in stage III non-small cell lung cancer

SAKK LuCa 2

Registry and study of EGFR-mutated NSCLC

salVage

Phase III randomized controlled trial comparing maintenance systemic therapy alone with systemic therapy plus local ablative treatment for patients with advanced stage IV non-small cell lung cancer

ETOP CHESS

A multicentre single arm phase II trial assessing the efficacy of radical immunotherapy and chemotherapy, stereotactic radiotherapy and surgery in patients with synchronous oligo-metastatic NSCLC

Study 22615

A Phase 3 study of BAY 2927088 compared to standard treatment in advanced non-small cell lung cancer (NSCLC) with HER2 mutations. Study 22615 ("SOHO-02")

Recruitment completed

ACHILES

ACHILES Does immunotherapy improve survival in patients with small cell lung cancer with limited disease who have received chemotherapy and radiotherapy?

ETOP ADOPT

An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

Recruitment completed

SAKK 15/19

Study SAKK 15/19 Radiation of lung tumor and maintenance therapy with durvalumab following treatment with chemotherapy and durvalumab in patients with advanced small cell lung cancer

Recruitment completed

SAKK 19/17

Study SAKK 19/17 - Durvalumab in patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC) and inadequate general condition - A multicenter single-arm phase II study.